A new drug for advanced prostate cancer has shown promise in early trials experts have said, with the medication shrinking tumors in some patients.
Prostate cancer is the most common cancer among men in many countries, including the US and UK. About 1.5 million men are diagnosed worldwide each year.
The new drug has caused excitement as it is a type of treatment called immunotherapy. This approach uses the body’s own immune system to fight disease, and has already proved beneficial for some cancers.
Photo: Bloomberg
However, experts say it has not yet had the same impact on prostate cancer.
Now scientists have reported results from an early stage trial of an immunotherapy drug called VIR-5500, suggesting it could offer hope to men with advanced prostate cancer.
“We believe that such treatments may in the long term lead to cures,” said Johann de Bono of the Institute of Cancer Research and the Royal Marsden NHS foundation trust, who led the work.
VIR-5500was an engineered antibody that brought together the body’s killer T-cells with tumor cells trying to evade them, De Bono said.
This type of drug, called a T-cell engager, allowed the killer cells to wipe out the tumor ones.
The special feature of VIR-5500 was that it was designed to only become activated within the tumor, De Bono added.
This not only minimized side effects — an important consideration as other T-cell engagers have been found to trigger severe inflammatory responses in people with prostate cancer — but allowed the drug to linger in the bloodstream, meaning fewer doses might be needed.
Under the phase one clinical trial, funded by Vir Biotechnology, 58 men with advanced prostate cancer, and who had stopped responding to other treatments, were given VIR-5500.
The researchers found the majority of patients — 88 percent — experienced only very mild side effects.
Then, they looked at the level of prostate-specific antigen (PSA) in the men’s blood — a biomarker whereby higher levels can be a sign of prostate conditions.
De Bono said the trial started at low doses, with the dose increasing in stages.
When the team looked at data for 17 men given the highest dose, they found that for 14 (82 percent) their PSA level fell by at least half after treatment, nine (53 percent) saw their PSA level fall by at least 90 percent, and five (29 percent) experienced a fall of at least 99 percent.
De Bono described the results as unprecedented for a disease previously thought to be “immune-cold,” in other words resistant to immunotherapy.
The team added that, of 11 people given the highest dose and whose tumors were measurable, five showed tumor shrinkage. In one case involving a 63-year-old man whose cancer had spread to his liver, the team found 14 cancerous liver lesions “completely resolved” after six cycles of treatment.
The results, which have not yet been peer-reviewed, were presented at the American Society of Clinical Oncology genitourinary cancers symposium in San Francisco.
Further clinical trials are now being planned, De Bono said.
“We do need more data, but the results are stunning,” he said.
Imperial College London cancer biology professor Charlotte Bevan, who was not involved in the work, said an advance in using immunotherapy for prostate cancer was potentially very exciting, opening up a new class of drug.
However, it was important studies were carried out with people of different ethnicities, as there were disparities in prostate cancer outcomes, she said.
Prostate Cancer UK assistant director of research Simon Grieveson described the early-phase trial as exciting.
“With over 12,000 men dying from prostate cancer each year in the UK, we urgently need new and innovative ways to treat the disease,” he said. “These early results are extremely promising, with a number of men on the study responding positively to the treatment with minimal side effects. I look forward to seeing this now tested in larger trials, with the hope that this treatment will offer men more valuable time with their loved ones.”
THE TRAGEDY OF PUNCH: Footage of the seven-month-old Japanese macaque has gone viral online after he was rejected by his mother and formed a bond with a soft toy A baby monkey in Japan has captured hearts around the world after videos of him being bullied by other monkeys and rejected by his mother went viral last week. Punch, a Japanese macaque, was born in July last year at Ichikawa City Zoo. He has drawn international attention after zookeepers gave him a stuffed orangutan toy after he was abandoned by his mother. Without maternal guidance to help him integrate, Punch has turned to the toy for comfort. He has been filmed multiple times being dragged and chased by older Japanese macaques inside the enclosure. Early clips showed him wandering alone with
South Korea would soon no longer be one of the few countries where Google Maps does not work properly, after its security-conscious government reversed a two-decade stance to approve the export of high-precision map data to overseas servers. The approval was made “on the condition that strict security requirements are met,” the South Korean Ministry of Land, Infrastructure and Transport said. Those conditions include blurring military and other sensitive security-related facilities, as well as restricting longitude and latitude coordinates for South Korean territory on products such as Google Maps and Google Earth, it said. The decision is expected to hurt Naver and Kakao
Australian Prime Minister Anthony Albanese yesterday said he did not take his security for granted, after he was evacuated from his residence for several hours following a bomb threat sent to a Chinese dance group. Albanese was evacuated from his Canberra residence late on Tuesday following the threat, and returned a few hours later after nothing suspicious was found. The bomb scare was among several e-mails threatening Albanese sent to a representative of Shen Yun, a classical Chinese dance troupe banned in China that is due to perform in Australia this month, a spokesperson for the group said in a statement. The e-mail
MONEY GRAB: People were rushing to collect bills scattered on the ground after the plane transporting money crashed, which an official said hindered rescue efforts A cargo plane carrying money on Friday crashed near Bolivia’s capital, damaging about a dozen vehicles on highway, scattering bills on the ground and leaving at least 15 people dead and others injured, an official said. Bolivian Minister of Defense Marcelo Salinas said the Hercules C-130 plane was transporting newly printed Bolivian currency when it “landed and veered off the runway” at an airport in El Alto, a city adjacent to La Paz, before ending up in a nearby field. Firefighters managed to put out the flames that engulfed the aircraft. Fire chief Pavel Tovar said at least 15 people died, but
RSS